eligibility_summary
Adults ≥18 with recurrent/persistent epithelial cervical cancer after ≥1 prior chemo (≤2 lines), measurable disease (RECIST v1.1), ECOG 0–1, adequate marrow/renal/hepatic function, archival FFPE for TROP‑2, ≥2‑week washout (4 wks for IO), not pregnant/breastfeeding, contraception required. Exclude: active CNS mets, significant cardiac/respiratory/unstable illness, recent other malignancy, active HIV/HBV/HCV, bleeding diathesis, Gilbert’s, bulky >7 cm, GI obstruction, irinotecan/topo I issues, UGT1A1 inhibitors, hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05838521. Intervention: Sacituzumab govitecan (IMMU-132, Trodelvy), an antibody–drug conjugate (ADC). Mechanism: a humanized anti–TROP-2 monoclonal antibody delivers SN-38 (active metabolite of irinotecan), a topoisomerase I inhibitor. After binding TROP-2 on tumor cells, the ADC is internalized and releases SN-38 via a hydrolyzable linker, inhibiting topo I, inducing DNA damage/replication stress and apoptosis, linker enables a bystander effect. Targets: TROP-2–expressing cervical epithelial cancer cells, DNA replication/repair via topoisomerase I. Phase 2, single-arm in recurrent/persistent disease.